BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Intelleflex Study Proves RFID Technology Safe for Use With Biologics


7/25/2012 9:52:10 AM

Reading, UK July 25, 2012 – Intelleflex, a leading provider of on-demand data visibility solutions for supply chains and asset tracking, supports the findings of a study published by the Parenteral Drug Association (PDA) that RFID technology is both safe and suitable for use in the presence of biologics. The study, “Effects of Radio Frequency Identification-related Radiation on In Vitro Biologics,” was conducted by researchers at The University of South Florida, Blood Center of Wisconsin, Abbott, Georgia Institute of Technology and the Madison RFID Lab at the University of Wisconsin and was published in the July-August edition of the PDA Journal of Pharmaceutical Science and Technology.

The report noted that RFID-based equipment could be used safely in close proximity to biologics, making the technology suitable for “track and trace” operations. The research showed that in vitro test results for more than 100 biopharmaceutical products from eight major drug companies demonstrated no non-thermal effect by radio frequency radiation.

The findings come in advance of forthcoming requirements mandated by ePedigree laws in California and Florida, which are expected to go into effect in 2015 and ultimately impact the entire pharmaceutical industry. Compliance with such laws will require a combination of RFID and 2D barcode technologies for monitoring the condition, authenticity and traceability of pharmaceuticals, including biologics. Temperature-monitoring RFID technology is critical to an accurate assessment of the condition of biologics, such as vaccines, medications and therapeutics, which are typically highly temperature sensitive and require constant monitoring to verify adherence to distribution protocols that ensure safety, quality and efficacy.

“We’re pleased that the results of this study prove that RFID technology is inherently safe when used with biologics,” said Peter Mehring, President and CEO of Intelleflex. “By using RFID for package-level temperature monitoring, producers of biologics can not only take preventive action to safeguard their products during shipping, warehousing, and delivery, but can also maintain end-to-end traceability of those products to address pending ePedigree and serialization requirements, all helping to ensure patient safety.”

To obtain a copy of the PDA article, visit http://journal.pda.org/content/66/4.toc. The report is available free to PDA members and available to non-members for a nominal fee.

About Intelleflex

Intelleflex® provides on-demand data visibility solutions for cold chain and asset management. Its industry-leading XC3 Technology™ RFID products enable a range of solutions for fresh produce, perishable food, and pharmaceutical temperature monitoring, asset tracking, personnel monitoring, retail, healthcare and other applications. These real-time monitoring solutions can help organizations reduce shrink or loss, more closely track and manage assets, reduce cost of operations, and increase profitability. For more information, visit www.intelleflex.com.

Intelleflex is a registered trademark, and XC3 Technology and ZEST Data Services are trademarks of Intelleflex. All other trademarked names in this document are the properties of their respective owners.

Editorial Contacts

Paul Scanlon

Jargon PR

01189 73 93 70

Paul.Scanlon@JargonPR.com

PRFilter

PRFilter is a relevance engine that filters press releases for users based on a personal profile of their interests created from their own, or their publication's, published articles. The public website also provides anyone with the ability to search thousands of releases from multiple sources or view the most relevant releases in particular areas of interest.

Releases marked with [PRFilter] in the subject line of RealWire release emails indicate PRFilter determined the release passed an individuals relevance threshold. Users can login and increase or decrease this threshold. Users can also train PRFilter to determine release relevance more accurately by providing feedback – “More”, this release is relevant or “Less”, this release is not relevant.

Please visit PRFilter to log in or contact RealWire for more information.

News Receiver Options

Receivers members area – the receivers members area allows you to amend your news category options and preferences, and access your own personal RSS feed of relevant news. Log in now or request log in details.

Unsubscribe – should you wish to unsubscribe from RealWire’s distribution, please click here. We would very much value your feedback on why you wish to be removed in order for us to continue to improve and develop our service.

Disclaimer:

Whilst RealWire Limited endeavour to ensure the accuracy of the information contained in this Release, RealWire Limited cannot accept any liability for:-

• the inaccuracy or otherwise of any information contained in this Release; or

• any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release; or

• any loss or suffering which may be caused by or to any party either as a result of the information contained in this Release or such information contained in this Release being inaccurate or otherwise misleading.

In the event that any information contained in this Release is inaccurate or misleading then please contact RealWire.

RealWire’s privacy policy is available on our website.

RealWire:

The registered address of RealWire is:

Realwire Limited, Unit 1, Exchange Close, North Hykeham, Lincoln, LN6 3TR. Realwire Limited is a company registered in England and Wales: 4026690


Read at BioSpace.com


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->